Moreover, there was a significant difference in the ratio of tumor-to-kidney uptake between responders and non-responders, and these values correlated with the mean dose (p < 0.01), making it possible to use pretherapy PSMA PET to estimate the response to treatment. Here, FOLH1 is linked to neoplasm.